Geraldine POENOU (@zudenstein) header
Geraldine POENOU (@zudenstein) profile picture

Associate Professor , to bleed or not to bleed 💚💚💚 happy mum

Joined March 2015
Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)Photo by Geraldine POENOU (@zudenstein)
Check out my first first author paper with the best team 🐍🐍. Thanks @MettineBos and Mark Schreuder for that great work together!!!
Proud of Mark Schreuder and @zudenstein 📰 in @TH_Journal on the activation peptide of venom factor X from the common brown snake 🐍 that transforms it into a powerful procoagulant protein and venom toxin - go Team Snakesss!🔥🧑‍🔬👩🏾‍🔬🔥 thieme-connect.com/products/…
1
8
MAJOR The U.S. Food and Drug Administration today approved Sunharbo (#asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a #stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” “Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke,” said Hylton V. Joffe, M.D., MMSc, Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA’s Center for Drug Evaluation and Research. “Today’s approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention.” The effectiveness of Sunharbo was demonstrated in the OCEANIC-STROKE study, a multicenter, randomized, double-blind, placebo-controlled phase 3 study that enrolled 12,327 adults. Participants had a recent non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or high-risk TIA and were randomly assigned to Sunharbo or placebo within 72 hours of symptom onset. Both groups also received antiplatelet therapy. Sunharbo 50 mg once daily significantly reduced the risk of ischemic stroke by 26% compared to placebo over a median treatment of 14.2 months. The overall rate of major bleeding was similar between the Sunharbo and placebo groups but was increased with Sunharbo in patients older than 75 years and during the first 90 days of treatment. Gastrointestinal bleeding occurred more commonly with Sunharbo compared to placebo. The most frequently reported adverse reaction (occurring in 3% or greater of Sunharbo-treated patients) was diarrhea. Concomitant use with medicines that are combined P-gp and strong CYP3A4 inducers (such as carbamazepine) is not recommended because these medicines may decrease Sunharbo’s effectiveness. Sunharbo is not recommended in patients with moderate or severe hepatic impairment. Sunharbo should be withheld at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolysis for acute ischemic stroke. Sunharbo is not approved for stroke prevention in patients with atrial fibrillation. The FDA granted Sunharbo Fast Track and Priority Review designations. The approval was granted to Bayer HealthCare Pharmaceuticals Inc., Whippany, N.J. fda.gov/news-events/press-an…
1
26
3
83
22,343
Geraldine POENOU retweeted
Iron Deficiency: NICE now recommended testing Ferritin in women with Heavy Periods. This is a change 20 years in the making and a huge step forwards to address the imbalance in healthcare affecting women In 1968 the WHO suggested screening women for anaemia
1
14
1
56
2,291
Rest in Peace to “Aya de Yopougon” illustrator Clement Oubrerie. With your colorful visuals and Abouet’s writing, Aya became one of the most beloved African stories 🕊️
12
1,267
100
5,293
102,804
Geraldine POENOU retweeted
The ISTH Pulse Podcast teamed up with #WorldThrombosisDay to spotlight hospital-associated VTE — one of the top preventable causes of death in hospitalized patients. Hear key global insights and prevention strategies: bit.ly/46WJjhT
5
10
581
Geraldine POENOU retweeted
Fascinating paper from Chrysaf @jzbos @LeaderAvi @rushadpatell et al suggesting nearly half the rate of VTE in individuals with FXI deficiency and cancer - important clinical mplications as FXI targeting agents are being developed for cancer VTE sciencedirect.com/science/ar…
5
11
484
Geraldine POENOU retweeted
Dans 70 centres urbains analysés en France: 1 habitant sur 4 n'a pas accès à un espace vert à moins de 10 min à pied limportant.fr/infos-planete/… @statista_fr
2
7
3,351
Geraldine POENOU retweeted
Exercizumab is real. Aerobic exercise cut colon cancer recurrence + death. It’s time to combine movement with medicine not one or the other. #oncology #Cancer @NEJM @OncoAlert @ASCO #ASCO25 DOI: 10.1056/NEJMoa2502760
2
56
2
220
16,380
Geraldine POENOU retweeted
🧠 #ISTH2025 SCC survey on stroke in cancer patients: 1️⃣ Physicians choose reperfusion strategies differently for patients with vs. without cancer 2️⃣ Antiplatelets remain the most used for secondary prevention regardless of cancer 3️⃣ Major equipoise on workup post-stroke in cancer What is the standard of care?
12
22
1,369
Geraldine POENOU retweeted
🩸 Clots tend to come back at the same site as the index VTE! Among 708 patients with prior VTE, recurrences often occurred at the same site as the original event, especially ipsilateral DVTs. Familiar symptoms? Trust your clinical instincts. #ISTH2025 #VTE #DVT
19
44
1,855
Timing initiating #heparin crucial in #pulmonary embolism mortality #ISTH2025 ⁦@Vasculearn⁩ ⁦@PERTConsortium⁩ ⁦@AnticoagForum⁩ ⁦@ThrombosisCan⁩ ⁦@thrombosisday⁩ ⁦@canvector⁩ ⁦@EuropeanTHA⁩ ⁦@Medscape⁩ ⁦@ThrombosisUK⁩
9
2
26
1,673
Geraldine POENOU retweeted
🔍 Thrombophilia testing? Knowing when and how to test is crucial — but so is knowing which lab to trust. The latest ISTH SSC guidance outlines best practices and recommendations for lab selection and testing reliability. Read it👇Share it Apply it #ISTH2025 #Hemostasis
1
25
61
5,139
Geraldine POENOU retweeted
🚨 In patients with intermediate–high risk PE, doubling the time to start anticoagulation is associated with a 2.7-fold increased risk of PE-related death. Timely treatment matters!! #VTE #ISTH2025
10
62
3,514
Geraldine POENOU retweeted
@gilles2206 @Echoraljpangio @lasfmv @ClubVasculaire @SevestreMarie @GMahe_ Le référentiel 2eme cycle de médecine et chirurgie vasculaire 4EME édition 2025 est disponible en librairie
6
6
320
Geraldine POENOU retweeted
World Hypertension Day: 10 Ways to Lower Your Blood Pressure 1️⃣ Healthy Diet: 11 mmHg 2️⃣ Isometric Exercises: 10/11 mmHg 3️⃣ Stress Reduction: 6/7 mmHg 4️⃣ Aerobic Exercises: 5/6 mmHg 5️⃣ 1Kg Weight loss: 5mmHg 6️⃣ Reduced sodium intake: 5/6 mmHg 7️⃣ Resistance Training: 4 mmHg 8️⃣ Reduced Alcohol Intake: 4 mmHg 9️⃣ Increased Potassium Intake: 3/4 mmHg 1️⃣0️⃣ 5 g/day Extra Fiber: 2-3 mmHg @NutritionMadeS3 @DrNadolsky @DrKarlNadolsky @drmatthewnagra @MichaelAlbertMd @MichaelMindrum @BevTchangMD @maciejbanach @drpablocorral @SABOURETCardio @ethanjweiss @DBelardoMD Great Paper To Know More: pubmed.ncbi.nlm.nih.gov/3771…
16
182
3
465
34,098
The Anatomy Lesson of Dr. Nicolaes Tulp, by Rembrandt, 1632 #histmed #DutchGoldenAge #anatomy #doctor #medstudent #medschool #pastmedicalhistory
1
36
3
151
11,255
Geraldine POENOU retweeted
The anticoagulant potency of #DOAC differs according to the individual procoagulant potential. Highly procoagulant plasmas from patients withcirrhosis are less sensitive to the anticoagulant action of apixaban, edoxaban, and rivaroxaban compared to control jthjournal.org/article/S1538…
7
15
1,129